Adult phenylketonuria outcome and management

Molecular Genetics and Metabolism

Volumn 104, Issue SUPPL., 2011, Pages

  Trefz, F ^a   Maillot, F ^b   Motzfeldt, K ^c   Schwarz, M ^d  

^a Kreiskliniken Reutlingen   (Germany)

^b UNIVERSITÉ DE TOURS   (France)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d Internal Medicine outpatient centre   (Germany)

Author keywords

Adult; Hyerphenylalaninemia; Phenylketonuria; Sapropterin

Indexed keywords

DOPAMINE; PHENYLALANINE;

ANXIETY; BODY GROWTH; BONE DENSITY; BRAIN DEVELOPMENT; COGNITION; DEPRESSION; DIET THERAPY; HUMAN; MENTAL PERFORMANCE; NEUROPSYCHOLOGICAL TEST; NEWBORN SCREENING; NUCLEAR MAGNETIC RESONANCE IMAGING; NUTRITIONAL DEFICIENCY; PHENYLKETONURIA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; WORKING MEMORY;

ADULT; CENTRAL NERVOUS SYSTEM; HUMANS; NUTRITIONAL STATUS; PHENYLKETONURIAS; TREATMENT OUTCOME;

EID: 82755182632     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2011.08.025     Document Type: Review

References (38)

1. Feillet F., van Spronsen F., MacDonald A., Trefz F.K., Demirkol M., Giovannini M., Bélanger-Quintana A., Blau N. Challenges and pitfalls in the management of phenylketonuria. Pediatrics 2010, 126:333-341.
2. Baumeister A.A., Baum eister A.A. Dietary treatment of destructive behavior associated with hyperphenylalaninemia. Clin. Neuropharmacol. 1998, 21:18-27.
3. Lee P.J., Amos A., Robertson L., Fitzgerald B., Hoskin R., Lilburn M., Weetch E., Murphy G.J. Adults with late diagnosed PKU and severe challenging behaviour: a randomised placebo-controlled trial of a phenylalanine-restricted diet. J. Neurol. Neurosurg. Psychiatry 2009, 80:631-635.
4. Trefz F.K., Cipcic-Schmidt S., Koch R. Final intelligence in late treated patients with phenylketonuria. Eur. J. Pediatr. 2000, 159(Suppl 2):S145-S148.
5. Grosse S.D. Late-treated phenylketonuria and partial reversibility of intellectual impairment. Child Dev. 2010, 81:200-211.
6. Seashore M.R., Friedman E., Novelly R.A., Bapat V. Loss of intellectual function in children with phenylketonuria after relaxation of dietary phenylalanine restriction. Pediatrics 1985, 75:226-232.
7. Koch R., Burton B., Hoganson G., Peterson R., Rhead W., Rouse B., Scott R., Wolff J., Stern A.M., Guttler F., Nelson M., de la Cruz F., Coldwell J., Erbe R., Geraghty M.T., Shear C., Thomas J., Azen C. Phenylketonuria in adulthood: a collaborative study. J. Inherit. Metab. Dis. 2002, 25:333-346.
8. National Institutes of Health Consensus Development Conference Statement: phenylketonuria: screening and management, October 16-18, 2000.
9. Moyle J.J., Fox A.M., Arthur M., Bynevelt M., Burnett J.R. Meta-analysis of neuropsychological symptoms of adolescents and adults with PKU. Neuropsychol. Rev. 2007, 17:91-101.
10. Feldmann R., Denecke J., Grenzebach M., Weglage J. Frontal lobe-dependent functions in treated phenylketonuria: blood phenylalanine concentrations and long-term deficits in adolescents and young adults. J. Inherit. Metab. Dis. 2005, 28:445-455.
11. Albrecht J., Garbade S.F., Burgard P. Neuropsychological speed tests and blood phenylalanine levels in patients with phenylketonuria: a meta-analysis. Neurosci. Biobehav. Rev. 2009, 33:414-421.
12. Brumm V.L., Azen C., Moats R.A., Stern A.M., Broomand C., Nelson M.D., Koch R. Neuropsychological outcome of subjects participating in the PKU adult collaborative study: a preliminary review. J. Inherit. Metab. Dis. 2004, 27:549-566.
13. Channon S., Goodman G., Zlotowitz S., Mockler C., Lee P.J. Effects of dietary management of phenylketonuria on long-term cognitive outcome. Arch. Dis. Child. 2007, 92:213-218.
14. Sundermann B., Pfleiderer B., Möller H.E., Schwindt W., Weglage J., Lepsien J., Feldmann R.T. Tackling frontal lobe-related functions in PKU through functional brain imaging: a Stroop task in adult patients. J. Inherit. Metab. Dis. 2011, 34:711-721.
15. ten Hoedt A.E., de Sonneville L.M., Francois B., ter Horst N.M., Janssen M.C., Rubio-Gozalbo M.E., Wijburg F.A., Hollak C.E., Bosch A.M. High phenylalanine levels directly affect mood and sustained attention in adults with phenylketonuria: a randomised, double-blind, placebo-controlled, crossover trial. J. Inherit. Metab. Dis. 2011, 34:165-171.
16. Dobbelaere D., Michaud L., Debrabander A., Vanderbecken S., Gottrand F., Turck D., Farriaux J.P. Evaluation of nutritional status and pathophysiology of growth retardation in patients with phenylketonuria. J. Inherit. Metab. Dis. 2003, 1-11.
17. Lage S., Bueno M., Andrade F., Prieto J.A., Delgado C., Legarda M., Sanjurjo P., Aldámiz-Echevarría L.J. Fatty acid profile in patients with phenylketonuria and its relationship with bone mineral density. J. Inherit. Metab. Dis. Sep. 10 2010, [Epub ahead of print].
18. Hoeksma M., Van Rijn M., Verkerk P.H., Bosch A.M., Mulder M.F., de Klerk J.B., de Koning T.J., Rubio-Gozalbo E., de Vries M., Sauer P.J., van Spronsen F.J. The intake of total protein, natural protein and protein substitute and growth of height and head circumference in Dutch infants with phenylketonuria. J. Inherit. Metab. Dis. 2005, 28:845-854.
19. Rocha J.C., Almeida M.F., Carmona C., Cardoso M.L., Borges N., Soares I., Salcedo G., Lima M.R., Azevedo I., van Spronsen F.J. The use of prealbumin concentration as a biomarker of nutritional status in treated phenylketonuric patients. Ann. Nutr. Metab. 2010, 56:207-211.
20. Modan-Moses D., Vered I., Schwartz G., Anikster Y., Abraham S., Segev R., Efrati O. Peak bone mass in patients with phenylketonuria. J. Inherit. Metab. Dis. 2007, 30:202-208.
21. Porta F., Mussa A., Zanin A., Greggio N.A., Burlina A., Spada M. Impact of metabolic control on bone quality in phenylketonuria and mild hyperphenylalaninemia. J. Pediatr. Gastroenterol. Nutr. 2011, 52:345-350.
22. Hvas A.M., Nexo E., Nielsen J.B. Vitamin B12 and vitamin B6 supplementation is needed among adults with phenylketonuria (PKU). J. Inherit. Metab. Dis. 2006, 29:47-53.
23. Vugteveen I., Hoeksma M., Monsen A.L., Fokkema M.R., Reijngoud D.J., van Rijn M., van Spronsen F.J. Serum vitamin B12 concentrations within reference values do not exclude functional vitamin B12 deficiency in PKU patients of various ages. Mol. Genet. Metab. 2011, 102:13-17.
24. Waisbren S.E., Noel K., Fahrbach K., Cella C., Frame D., Dorenbaum A., Levy H. Phenylalanine blood levels and clinical outcomes in phenylketonuria: a systematic literature review and meta-analysis. Mol. Genet. Metab. 2007, 92:63-70.
25. Viau K.S., Wengreen H.J., Ernst S.L., Cantor N.L., Furtado L.V., Longo N. Correlation of age-specific phenylalanine levels with intellectual outcome in patients with phenylketonuria. J. Inherit. Metab. Dis. May 10 2011, [Epub ahead of print].
26. Burgard P., Rupp A., Konecki D.S., Trefz F.K., Schmidt H., Lichter-Konecki U. Phenylalanine hydroxylase genotypes, predicted residual enzyme activity and phenotypic parameters of diagnosis and treatment of phenylketonuria. Eur. J. Pediatr. 1996, 155(Suppl 1):S11-S15.
27. Anastasoaie V., Laura K., Forbes P., Waisbren S. Stability of blood phenylalanine levels and IQ in children with phenylketonuria. Mol. Genet. Metab. 2008, 95:17-20.
28. Luciana M., Sullivan J., Nelson C.A. Associations between phenylalanine-to-tyrosine ratios and performance on tests of neuropsychological function in adolescents treated early and continuously for phenylketonuria. Child Dev. 2001, 72:1637-1652.
29. Pérez-Dueñas B., Pujol J., Soriano-Mas C., Ortiz H., Artuch R., Vilaseca M.A., Campistol J. Global and regional volume changes in the brains of patients with phenylketonuria. Neurology 2006, 66:1074-1078.
30. Ding X.Q., Fiehler J., Kohlschütter B., Wittkugel O., Grzyska U., Zeumer H., Ullrich K. MRI abnormalities in normal-appearing brain tissue of treated adult PKU patients. Magn. Reson. Imaging 2008, 27:998-1004.
31. Anderson P.J., Leuzzi V. White matter pathology in phenylketonuria. Mol. Genet. Metab. 2010, 99(Suppl 1):S3-S9.
32. Landvogt C., Mengel E., Bartenstein P., Buchholz H.G., Schreckenberger M., Siessmeier T., Scheurich A., Feldmann R., Weglage J., Cumming P., Zepp F., Ullrich K. Reduced cerebral fluoro-L-dopamine uptake in adult patients suffering from phenylketonuria. J. Cereb. Blood Flow Metab. 2008, 28:824-831.
33. Hoeksma M., Reijngoud D.J., Pruim J., de Valk H.W., Paans A.M., van Spronsen F.J. Phenylketonuria: high plasma phenylalanine decreases cerebral protein synthesis. Mol. Genet. Metab. 2009, 96:177-182.
34. Walter J.H., White F.J. Blood phenylalanine control in adolescents with phenylketonuria. Int. J. Adolesc. Med. Health 2004, 16:41-45.
35. Blau N., van Spronsen F.J., Levy H.L. Phenylketonuria. Lancet 2010, 376:1417-1427.
36. Levy H.L., Milanowski A., Chakrapani A., Cleary M., Lee P., Trefz F.K., Chester B., Whitley C.B., Feillet F., Feigenbaum A.S., Bebchuk J.D., Christ-Schmidt H., Dorenbaum A. Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomised placebo-controlledstudy. Lancet 2007, 370:504-510. for the Sapropterin Research Group*.
37. Trefz F.K., Burton B.K., Longo N., Casanova M.M., Gruskin D.J., Dorenbaum A., Kakkis E.D., Crombez E.A., Grange D.K., Harmatz P., Lipson M.H., Milanowski A., Randolph L.M., Vockley J., Whitley C.B., Wolff J.A., Bebchuk J., Christ-Schmidt H., Hennermann J.B. Efficacy of sapropterin dihydrochloride in increasing phenylalanine tolerance in children with phenylketonuria: a phase III, randomized, double-blind, placebo-controlled study. J. Pediatr. 2009, 154:700-707. Sapropterin Study Group.
38. Burton B.K., Bausell H., Katz R., Laduca H., Sullivan C. Sapropterin therapy increases stability of blood phenylalanine levels in patients with BH4-responsive phenylketonuria (PKU). Mol. Genet. Metab. 2010, 101:110-114.